Researchglp-1 receptor agonistsend-stage kidney diseasebariatric surgerytype 2 diabetes

GLP-1 users on dialysis show lower mortality than DPP-4 inhibitor users

A target trial emulation in the US Renal Data System also found bariatric surgery carried higher one-year mortality than GLP-1 therapy but more transplant waitlisting.

By Priya Raman · Science Reporter

Sep 20 20:00 ETSource: Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

The wire

01Using 2010-2022 USRDS data, researchers emulated three trials in adults with end-stage kidney disease, type 2 diabetes and at least class II obesity: surgery versus GLP-1 (N=1818), surgery versus DPP-4i (N=2111) and GLP-1 versus DPP-4i (N=4338).
02Bariatric surgery carried higher short-term mortality than matched GLP-1 users (1-year aHR 2.68, 95% CI 1.98-3.63) but comparable long-term mortality, while GLP-1 users consistently outlived DPP-4i users.
03Surgery was associated with more kidney transplant waitlisting than either drug; this is observational registry analysis with residual confounding despite matching and active-comparator design.

From the source

Metabolic bariatric surgery versus GLP-1 receptor agonists in dialysis patients with diabetes and obesity: a target trial emulation study
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2026 Sep 21 · Gao C, Menon G, Chen Y et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42907282/